Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 11/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 7/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ARRB1 | P49407 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL15501048 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13076870 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2997 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL5183254 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13696339 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8049464 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL24599520 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL7987114 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL10820235 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL10031250 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9648815-B2 | Papaver somniferum with high concentration of codeine | TASMANIAN ALKALOIDS PTY. LTD. (AU) | 2017-05-16 | — | — | US | disclosed |
| US-8748416-B1 | Opioid salts and formulations exhibiting anti-abuse and anti-dumping properties | PISGAH LABORATORIES, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8541647-B2 | Papaver somniferum with high concentration of codeine | Tasmania Alkaloids Pty, Ltd. (AU) | 2013-09-24 | — | — | US | disclosed |
| US-20130205452-A1 | PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE | TASMANIA ALKALOIDS PTY. LTD. (AU) | 2013-08-08 | — | — | US | disclosed |
| US-8476291-B1 | Opioid salts and formulations exhibiting anti-abuse and anti-dumping properties | PISGAH LABORATORIES, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120302594-A1 | QUATERNARY OPIOID CARBOXAMIDES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2012-11-29 | — | — | US | disclosed |
| US-20100234600-A1 | PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE | CERBERUS BUSINESS FINANCE, LLC, AS COLLATERAL AGENT | 2010-09-16 | — | — | US | disclosed |
| US-7557119-B2 | analgesics, antidiarrheal agents, anticonvulsants, antitussives, anti-addiction; 8-Substituted-2,6-methano-3-benzazocines | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2009-07-07 | — | — | US | disclosed |
| US-20070021457-A1 | analgesics, antidiarrheal agents, anticonvulsants, antitussives, anti-addiction; 8-Substituted-2,6-methano-3-benzazocines | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021457-A1 | analgesics, antidiarrheal agents, anticonvulsants, antitussives, anti-addiction; 8-Substituted-2,6-methano-3-benzazocines | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885OPRD1 5/4885OPRK1 2/4885 |
| US-20120302594-A1 | QUATERNARY OPIOID CARBOXAMIDES | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
| US-20100234600-A1 | PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE | OPRM1, OPRK1, POF1B | OPRM1 1/4885OPRD1 5/4885OPRK1 2/4885 |
| US-20130205452-A1 | PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE | OPRM1, OPRK1, POF1B | OPRM1 1/4885OPRD1 5/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.